AC Immune Presents TDP-43 Imaging Data
AC Immune announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its positron emission tomography - PET - tracer ACI-19626, at the International Conference on Alzheimer's and Parkinson's Disease. Initial data from the Phase 1 trial support ACI-19626's potential to detect pathological TDP-43 in the brains of patients with TDP-43 proteinopathies, enabling a precision medicine approach to multiple neurodegenerative diseases. Specifically, PET scans with ACI-19626 showed that tracer uptake was significantly higher in key regions of the brain in patients with frontotemporal dementia due to mutated C9orf72 than in the brains of healthy subjects. ACI-19626 showed good safety and tolerability, a dosimetry profile within accepted limits, and rapid brain uptake and washout, indicating a PK profile suitable for human brain imaging and potentially pharmacodynamic analysis of therapeutics targeting TDP-43 pathology. This potentially enables precision medicine across multiple neurodegenerative diseases.
Trade with 70% Backtested Accuracy
Analyst Views on ACIU
About ACIU
About the author
AC Immune Reports FY 2023 Financial Results with Significant Revenue Decline
- Financial Performance Decline: AC Immune reported a FY 2023 GAAP EPS of -CHF0.70 and revenue of CHF3.57 million, reflecting an 86.9% year-over-year decline, indicating significant pressure on the company's market position and profitability.
- R&D Progress Stalled: While maintaining a 'Buy' rating on the development of ACI-7104.056 for PDAC, AC Immune's partner Johnson & Johnson has paused enrollment in the mid-stage trial for its Alzheimer's drug, which could impact future R&D timelines and market outlook.
- Negative Market Reaction: The substantial deterioration in financial data and uncertainty surrounding R&D progress have shaken market confidence in AC Immune, potentially leading to short-term stock price pressure and affecting investor sentiment.
- Historical Performance Review: Historical earnings data for AC Immune shows that despite current challenges, the company has had notable successes in the past, suggesting that strategic adjustments and innovation will be crucial for restoring growth moving forward.
AC IMMUNE SA: CHF 91.4 MILLION IN CASH RESOURCES AS OF DECEMBER 31, 2025, ENSURES FUNDING UNTIL Q3 2027
- Funding Overview: Cash resources of CHF 91.4 million are available as of December 31, 2025.
- Funding Timeline: These resources are intended to provide funding until the end of Q3 2027.
AC Immune and Johnson & Johnson Pause Alzheimer's Mid-Stage Trial
- Trial Suspension: AC Immune's mid-stage trial ReTain for the Alzheimer's candidate ACI-35.030/JNJ-2056 has temporarily paused enrollment as partner Johnson & Johnson evaluates various aspects of the trial, including recruitment, which may impact the drug's market entry timeline.
- Financial Stability: Despite the trial's pause, AC Immune has stated that J&J's decision will not affect its liquidity position, as existing capital resources are sufficient to fund operational needs into Q3 2027, ensuring stability in its R&D efforts.
- Collaboration Background: The drug's development stems from a licensing and commercialization agreement signed in 2015, allowing AC Immune to initially receive up to $509 million from J&J, highlighting the long-term collaborative potential in Alzheimer's treatment.
- Market Reaction: AC Immune's stock price may be affected by the trial suspension news; although the company has confirmed liquidity is secure, investor concerns regarding the drug's development progress could lead to short-term market volatility.
AC Immune Study Indicates Promising Early Results for Immunotherapy in Slowing Parkinson's Disease
Interim Results from VacSYn Trial: AC Immune SA reported promising interim safety and efficacy results from its Phase 2 VacSYn trial for the anti-alpha-synuclein immunotherapy ACI-7104.056, indicating potential slowing of Parkinson's disease progression through stabilization of disease-related biomarkers.
Robust Antibody Response: The treatment induced a strong antibody response against the target antigen, with a 100% responder rate and significantly higher antibody levels in both serum and cerebrospinal fluid compared to the placebo group.
Clinical Measures of Stabilization: Clinical assessments showed that the ACI-7104.056 group did not experience meaningful progression in motor symptoms, contrasting with the expected increase in the placebo group, suggesting a trend toward disease stabilization.
Future Expectations: The trial results are generally safe and well-tolerated, with final data from Part 1 of the VacSYn trial anticipated in mid-2026, while AC Immune's stock saw a notable increase following the announcement.
AC Immune's ACI-7104.056 Significantly Slows Parkinson's Disease Progression
- Clinical Trial Success: AC Immune's Phase 2 VacSYn trial of ACI-7104.056 demonstrates, for the first time, that targeting alpha-synuclein pathology with active immunotherapy may slow the progression of Parkinson's disease, marking a significant breakthrough in treatment.
- Strong Safety Profile: The therapy was administered to 34 patients, all treated for at least 12 months, with no clinically relevant adverse events reported, indicating a favorable safety and tolerability profile.
- Robust Immune Response: By week 76, the ACI-7104.056 group exhibited antibody titers over 500 times higher than the placebo group, achieving a 100% responder rate, showcasing the therapy's potential to induce a strong immune response and laying the groundwork for future treatments.
- Stabilization of Biomarkers: The treatment group showed stable levels of neurofilament light chain (NfL), a marker of neuronal damage, while levels increased in the placebo group, suggesting that the therapy may effectively slow neuronal damage, which has significant clinical implications.
AC Immune's ACI-7104.056 Shows Significant Slowing of Parkinson's Disease Progression
- Clinical Trial Results: AC Immune's Phase 2 VacSYn trial demonstrates for the first time that the active immunotherapy ACI-7104.056 may slow the progression of Parkinson's disease by targeting alpha-synuclein pathology, marking a significant breakthrough in treatment options.
- Safety and Immunogenicity: The therapy achieved a 100% responder rate in a cohort of 34 patients with no clinically relevant safety issues reported, indicating a strong safety profile and tolerability that supports further development.
- Biomarker Stability: In the treatment group, levels of alpha-synuclein in cerebrospinal fluid remained stable, contrasting with a decline in the placebo group, suggesting that ACI-7104.056 may stabilize pathology through antibody binding, indicating potential disease-modifying effects.
- Future Development Plans: Following these promising interim results, AC Immune aims to engage with regulators to discuss a clinical development plan for ACI-7104.056, with the goal of accelerating the registration process, and final data from the trial are expected in mid-2026.
AC Immune Reports FY 2023 Financial Results with Significant Revenue Decline
- Financial Performance Decline: AC Immune reported a FY 2023 GAAP EPS of -CHF0.70 and revenue of CHF3.57 million, reflecting an 86.9% year-over-year decline, indicating significant pressure on the company's market position and profitability.
- R&D Progress Stalled: While maintaining a 'Buy' rating on the development of ACI-7104.056 for PDAC, AC Immune's partner Johnson & Johnson has paused enrollment in the mid-stage trial for its Alzheimer's drug, which could impact future R&D timelines and market outlook.
- Negative Market Reaction: The substantial deterioration in financial data and uncertainty surrounding R&D progress have shaken market confidence in AC Immune, potentially leading to short-term stock price pressure and affecting investor sentiment.
- Historical Performance Review: Historical earnings data for AC Immune shows that despite current challenges, the company has had notable successes in the past, suggesting that strategic adjustments and innovation will be crucial for restoring growth moving forward.
AC IMMUNE SA: CHF 91.4 MILLION IN CASH RESOURCES AS OF DECEMBER 31, 2025, ENSURES FUNDING UNTIL Q3 2027
- Funding Overview: Cash resources of CHF 91.4 million are available as of December 31, 2025.
- Funding Timeline: These resources are intended to provide funding until the end of Q3 2027.
AC Immune and Johnson & Johnson Pause Alzheimer's Mid-Stage Trial
- Trial Suspension: AC Immune's mid-stage trial ReTain for the Alzheimer's candidate ACI-35.030/JNJ-2056 has temporarily paused enrollment as partner Johnson & Johnson evaluates various aspects of the trial, including recruitment, which may impact the drug's market entry timeline.
- Financial Stability: Despite the trial's pause, AC Immune has stated that J&J's decision will not affect its liquidity position, as existing capital resources are sufficient to fund operational needs into Q3 2027, ensuring stability in its R&D efforts.
- Collaboration Background: The drug's development stems from a licensing and commercialization agreement signed in 2015, allowing AC Immune to initially receive up to $509 million from J&J, highlighting the long-term collaborative potential in Alzheimer's treatment.
- Market Reaction: AC Immune's stock price may be affected by the trial suspension news; although the company has confirmed liquidity is secure, investor concerns regarding the drug's development progress could lead to short-term market volatility.
AC Immune Study Indicates Promising Early Results for Immunotherapy in Slowing Parkinson's Disease
Interim Results from VacSYn Trial: AC Immune SA reported promising interim safety and efficacy results from its Phase 2 VacSYn trial for the anti-alpha-synuclein immunotherapy ACI-7104.056, indicating potential slowing of Parkinson's disease progression through stabilization of disease-related biomarkers.
Robust Antibody Response: The treatment induced a strong antibody response against the target antigen, with a 100% responder rate and significantly higher antibody levels in both serum and cerebrospinal fluid compared to the placebo group.
Clinical Measures of Stabilization: Clinical assessments showed that the ACI-7104.056 group did not experience meaningful progression in motor symptoms, contrasting with the expected increase in the placebo group, suggesting a trend toward disease stabilization.
Future Expectations: The trial results are generally safe and well-tolerated, with final data from Part 1 of the VacSYn trial anticipated in mid-2026, while AC Immune's stock saw a notable increase following the announcement.
AC Immune's ACI-7104.056 Significantly Slows Parkinson's Disease Progression
- Clinical Trial Success: AC Immune's Phase 2 VacSYn trial of ACI-7104.056 demonstrates, for the first time, that targeting alpha-synuclein pathology with active immunotherapy may slow the progression of Parkinson's disease, marking a significant breakthrough in treatment.
- Strong Safety Profile: The therapy was administered to 34 patients, all treated for at least 12 months, with no clinically relevant adverse events reported, indicating a favorable safety and tolerability profile.
- Robust Immune Response: By week 76, the ACI-7104.056 group exhibited antibody titers over 500 times higher than the placebo group, achieving a 100% responder rate, showcasing the therapy's potential to induce a strong immune response and laying the groundwork for future treatments.
- Stabilization of Biomarkers: The treatment group showed stable levels of neurofilament light chain (NfL), a marker of neuronal damage, while levels increased in the placebo group, suggesting that the therapy may effectively slow neuronal damage, which has significant clinical implications.
AC Immune's ACI-7104.056 Shows Significant Slowing of Parkinson's Disease Progression
- Clinical Trial Results: AC Immune's Phase 2 VacSYn trial demonstrates for the first time that the active immunotherapy ACI-7104.056 may slow the progression of Parkinson's disease by targeting alpha-synuclein pathology, marking a significant breakthrough in treatment options.
- Safety and Immunogenicity: The therapy achieved a 100% responder rate in a cohort of 34 patients with no clinically relevant safety issues reported, indicating a strong safety profile and tolerability that supports further development.
- Biomarker Stability: In the treatment group, levels of alpha-synuclein in cerebrospinal fluid remained stable, contrasting with a decline in the placebo group, suggesting that ACI-7104.056 may stabilize pathology through antibody binding, indicating potential disease-modifying effects.
- Future Development Plans: Following these promising interim results, AC Immune aims to engage with regulators to discuss a clinical development plan for ACI-7104.056, with the goal of accelerating the registration process, and final data from the trial are expected in mid-2026.
